JP2016518332A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016518332A5 JP2016518332A5 JP2016502005A JP2016502005A JP2016518332A5 JP 2016518332 A5 JP2016518332 A5 JP 2016518332A5 JP 2016502005 A JP2016502005 A JP 2016502005A JP 2016502005 A JP2016502005 A JP 2016502005A JP 2016518332 A5 JP2016518332 A5 JP 2016518332A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- antigen
- binding fragment
- drug conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims description 59
- 239000000427 antigen Substances 0.000 claims description 58
- 102000036639 antigens Human genes 0.000 claims description 58
- 108091007433 antigens Proteins 0.000 claims description 58
- 239000000611 antibody drug conjugate Substances 0.000 claims description 55
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 55
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 claims description 19
- 239000003112 inhibitor Substances 0.000 claims description 14
- 101000827688 Homo sapiens Fibroblast growth factor receptor 2 Proteins 0.000 claims description 13
- 102000055736 human FGFR2 Human genes 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- -1 4-methyl-1-oxopentyl Chemical group 0.000 claims description 9
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 5
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 5
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 5
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims description 4
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 101150029707 ERBB2 gene Proteins 0.000 claims description 3
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims description 3
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims description 3
- 229940125644 antibody drug Drugs 0.000 claims description 3
- 239000003431 cross linking reagent Substances 0.000 claims description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 3
- 102000001708 Protein Isoforms Human genes 0.000 claims description 2
- 108010029485 Protein Isoforms Proteins 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 239000000562 conjugate Substances 0.000 claims description 2
- 230000001268 conjugating effect Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 description 10
- 102000055699 human FGFR4 Human genes 0.000 description 9
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- VRDGQQTWSGDXCU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-iodoacetate Chemical compound ICC(=O)ON1C(=O)CCC1=O VRDGQQTWSGDXCU-UHFFFAOYSA-N 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical group O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 description 2
- GTBCXYYVWHFQRS-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)pentanoate Chemical compound C=1C=CC=NC=1SSC(C)CCC(=O)ON1C(=O)CCC1=O GTBCXYYVWHFQRS-UHFFFAOYSA-N 0.000 description 2
- BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 description 2
- 239000012664 BCL-2-inhibitor Substances 0.000 description 2
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 2
- 229940125831 FGFR2 inhibitor Drugs 0.000 description 2
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 2
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 2
- 102100027670 Islet amyloid polypeptide Human genes 0.000 description 2
- 101710181812 Methionine aminopeptidase Proteins 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- FUHCFUVCWLZEDQ-UHFFFAOYSA-N 1-(2,5-dioxopyrrolidin-1-yl)oxy-1-oxo-4-(pyridin-2-yldisulfanyl)butane-2-sulfonic acid Chemical compound O=C1CCC(=O)N1OC(=O)C(S(=O)(=O)O)CCSSC1=CC=CC=N1 FUHCFUVCWLZEDQ-UHFFFAOYSA-N 0.000 description 1
- GWEVSJHKQHAKNW-UHFFFAOYSA-N 4-[[1-(2,5-dioxopyrrolidin-1-yl)-2h-pyridin-2-yl]disulfanyl]-2-sulfobutanoic acid Chemical compound OC(=O)C(S(O)(=O)=O)CCSSC1C=CC=CN1N1C(=O)CCC1=O GWEVSJHKQHAKNW-UHFFFAOYSA-N 0.000 description 1
- 229940121819 ATPase inhibitor Drugs 0.000 description 1
- 101100004408 Arabidopsis thaliana BIG gene Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 239000012624 DNA alkylating agent Substances 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 239000012626 DNA minor groove binder Substances 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 101100485279 Drosophila melanogaster emb gene Proteins 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 102100029095 Exportin-1 Human genes 0.000 description 1
- 229940125497 HER2 kinase inhibitor Drugs 0.000 description 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 1
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 1
- 102000010638 Kinesin Human genes 0.000 description 1
- 108010063296 Kinesin Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 229940119336 Microtubule stabilizer Drugs 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- 101100485284 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CRM1 gene Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 101150094313 XPO1 gene Proteins 0.000 description 1
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 108010044540 auristatin Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 108700002148 exportin 1 Proteins 0.000 description 1
- 101150088071 fgfr2 gene Proteins 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780299P | 2013-03-13 | 2013-03-13 | |
| US61/780,299 | 2013-03-13 | ||
| PCT/US2014/025944 WO2014160160A2 (en) | 2013-03-13 | 2014-03-13 | Antibody drug conjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019079590A Division JP2019193626A (ja) | 2013-03-13 | 2019-04-18 | 抗体薬物コンジュゲート |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016518332A JP2016518332A (ja) | 2016-06-23 |
| JP2016518332A5 true JP2016518332A5 (enExample) | 2017-04-13 |
Family
ID=50897870
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502005A Pending JP2016518332A (ja) | 2013-03-13 | 2014-03-13 | 抗体薬物コンジュゲート |
| JP2019079590A Pending JP2019193626A (ja) | 2013-03-13 | 2019-04-18 | 抗体薬物コンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019079590A Pending JP2019193626A (ja) | 2013-03-13 | 2019-04-18 | 抗体薬物コンジュゲート |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9498532B2 (enExample) |
| EP (1) | EP2968592A2 (enExample) |
| JP (2) | JP2016518332A (enExample) |
| KR (1) | KR20150130333A (enExample) |
| CN (1) | CN105188763B (enExample) |
| AR (1) | AR096015A1 (enExample) |
| AU (2) | AU2014244060B2 (enExample) |
| BR (1) | BR112015023418A8 (enExample) |
| CA (1) | CA2904090A1 (enExample) |
| EA (1) | EA201591611A1 (enExample) |
| MX (1) | MX2015012122A (enExample) |
| TW (1) | TW201444574A (enExample) |
| UY (1) | UY35399A (enExample) |
| WO (1) | WO2014160160A2 (enExample) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| TWI669313B (zh) | 2012-04-09 | 2019-08-21 | 第一三共股份有限公司 | 抗ＦＧＦＲ２抗體及其製造方法、及檢測或測定人類ＦＧＦＲ２ＩＩＩｂ之方法 |
| UA125503C2 (uk) | 2012-06-13 | 2022-04-13 | Інсайт Холдинґс Корпорейшн | Заміщені трициклічні сполуки як інгібітори fgfr |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| US9415118B2 (en) | 2013-03-13 | 2016-08-16 | Novartis Ag | Antibody drug conjugates |
| MY181497A (en) | 2013-04-19 | 2020-12-23 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| ME03476B (me) | 2013-08-01 | 2020-01-20 | Five Prime Therapeutics Inc | Nefukozilisana anti-fgfr2iiib antitijela |
| TWI541022B (zh) * | 2013-12-18 | 2016-07-11 | 應克隆公司 | 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法 |
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| CA2936962C (en) | 2014-03-14 | 2024-03-05 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| CA2964367C (en) | 2014-10-14 | 2024-01-30 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| SG11201703446RA (en) * | 2014-10-31 | 2017-05-30 | Abbvie Biotherapeutics Inc | Anti-cs1 antibodies and antibody drug conjugates |
| CN107592813A (zh) | 2014-11-19 | 2018-01-16 | 伊缪诺金公司 | 用于制备细胞结合剂‑细胞毒性剂缀合物的方法 |
| US20170340733A1 (en) | 2014-12-19 | 2017-11-30 | Novartis Ag | Combination therapies |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| HK1247089A1 (zh) | 2015-03-10 | 2018-09-21 | Aduro Biotech, Inc. | 用於活化“干扰素基因刺激物”依赖性信号传导的组合物和方法 |
| EP3287522A4 (en) * | 2015-04-20 | 2019-03-27 | Daiichi Sankyo Company, Limited | DETECTION OF FGFR2 |
| EP3095465A1 (en) | 2015-05-19 | 2016-11-23 | U3 Pharma GmbH | Combination of fgfr4-inhibitor and bile acid sequestrant |
| MX392478B (es) | 2015-06-22 | 2025-03-24 | Bayer Pharma AG | Conjugados de ligador-principio activo (adcs) y conjugados de ligador-profarmaco (apdcs) con grupos enzimaticamente escindibles. |
| CN107921146A (zh) * | 2015-06-23 | 2018-04-17 | 拜耳医药股份有限公司 | 纺锤体驱动蛋白(ksp)抑制剂与抗‑cd123的抗体的抗体药物缀合物(adc) |
| US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
| WO2017019896A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| EP4477269A3 (en) * | 2015-09-20 | 2025-03-19 | The United States of America, as Represented By the Secretary, Department of Health and Human Services | Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use |
| WO2017060322A2 (en) * | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| BR112018008891A8 (pt) | 2015-11-03 | 2019-02-26 | Janssen Biotech Inc | anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos |
| CN106699889A (zh) | 2015-11-18 | 2017-05-24 | 礼进生物医药科技（上海）有限公司 | 抗pd-1抗体及其治疗用途 |
| KR20250034528A (ko) | 2015-11-23 | 2025-03-11 | 파이브 프라임 테라퓨틱스, 인크. | 암 치료에서의 단독의, 또는 면역 자극제와 병용한, fgfr2 억제제 |
| WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| MA43660A (fr) | 2016-01-22 | 2018-11-28 | Adimab Llc | Anticorps anti-facteur xi de coagulation |
| KR20180105233A (ko) | 2016-02-05 | 2018-09-27 | 이뮤노젠 아이엔씨 | 세포 결합제-세포독성제 접합체를 제조하기 위한 효율적인 방법 |
| EP3414267B1 (en) | 2016-02-10 | 2023-12-27 | BioInvent International AB | Combination of human anti-fgfr4 antibody and sorafenib |
| WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| TWI752964B (zh) | 2016-06-14 | 2022-01-21 | 美商默沙東藥廠 | 抗凝血因子ｘｉ抗體 |
| EP3471776B1 (en) | 2016-06-15 | 2022-05-04 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates with ksp inhibitors and anti-cd123-antibodies |
| US11098077B2 (en) | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| US11660351B2 (en) | 2016-12-21 | 2023-05-30 | Bayer Aktiengesellschaft | Antibody drug conjugates (ADCs) having enzymatically cleavable groups |
| JP7030811B2 (ja) | 2016-12-21 | 2022-03-07 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ｋｓｐ阻害剤を有する特異的抗体－薬物コンジュゲート（ａｄｃ） |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| PT3624837T (pt) | 2017-05-16 | 2025-10-01 | Five Prime Therapeutics Inc | Anticorpos anti-fgfr2 em combinação com agentes quimioterapêuticos no tratamento do cancro |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| US20200172628A1 (en) | 2017-06-22 | 2020-06-04 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| EP3444275A1 (en) | 2017-08-16 | 2019-02-20 | Exiris S.r.l. | Monoclonal antibody anti-fgfr4 |
| MX2020002303A (es) | 2017-08-30 | 2020-09-10 | Beijing Xuanyi Pharmasciences Co Ltd | Dinucleotidos ciclicos como moduladores del estimulador de genes de interferon. |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| BR112020022392A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | formas sólidas de um inibidor de fgfr e processos para preparação das mesmas |
| PE20210919A1 (es) | 2018-05-04 | 2021-05-19 | Incyte Corp | Sales de un inhibidor de fgfr |
| TWI869346B (zh) | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
| WO2019246572A1 (en) * | 2018-06-22 | 2019-12-26 | Children's Medical Center Corporation | Compositions and methods for treating primary aldosteonism |
| WO2019246571A1 (en) * | 2018-06-22 | 2019-12-26 | Children's Medical Center Corporation | Compositions and methods for treating adrenocortical carcinoma |
| KR20220032646A (ko) | 2018-12-21 | 2022-03-15 | 오제 이뮈노테라프틱스 | 인간화된 항-인간-pd-1 항체 |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US20230092679A1 (en) * | 2019-05-20 | 2023-03-23 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US20220348651A1 (en) | 2019-09-18 | 2022-11-03 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| PE20221504A1 (es) | 2019-12-04 | 2022-09-30 | Incyte Corp | Derivados de un inhibidor de fgfr |
| JP7720840B2 (ja) | 2019-12-04 | 2025-08-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| US20220111063A1 (en) * | 2019-12-18 | 2022-04-14 | National University Corporation Okayama University | Antibody-drug conjugates and use of antibodies for drug delivery |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JP2023528454A (ja) * | 2020-06-03 | 2023-07-04 | ザ・ブロード・インスティテュート・インコーポレイテッド | 線維芽細胞増殖因子受容体２に特異的に結合する二重パラトープアンタゴニスト抗体およびその使用方法 |
| WO2022031935A1 (en) | 2020-08-05 | 2022-02-10 | Dragonfly Therapeutics, Inc. | Antibodies targeting egfr and use thereof |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313611A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| WO2023107954A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
| AU2023280994A1 (en) * | 2022-06-01 | 2024-12-12 | Cornell University | Cancer immunotherapies to promote hyperacute rejection |
| CN115645526B (zh) * | 2022-12-27 | 2023-03-21 | 中国人民解放军军事科学院军事医学研究院 | 溶菌酶c特异性抗体在制备治疗肝癌的药物中的应用 |
| EP4509142A1 (en) * | 2023-08-16 | 2025-02-19 | Ona Therapeutics S.L. | Fgfr4 as target in cancer treatment |
| WO2025257185A1 (en) | 2024-06-11 | 2025-12-18 | Abcely | Humanized anti-human-carcinoembryonic antigen antibody |
Family Cites Families (127)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US633410A (en) | 1898-09-22 | 1899-09-19 | George A Ames | Ice-cutter. |
| US2429001A (en) | 1946-12-28 | 1947-10-14 | Axel H Stone | Artificial hand |
| US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
| US3720760A (en) | 1968-09-06 | 1973-03-13 | Pharmacia Ab | Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples |
| US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
| US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
| JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| EP0092918B1 (en) | 1982-04-22 | 1988-10-19 | Imperial Chemical Industries Plc | Continuous release formulations |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| AU6430190A (en) | 1989-10-10 | 1991-05-16 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| EP0550436A1 (en) | 1989-11-06 | 1993-07-14 | Alkermes Controlled Therapeutics, Inc. | Protein microspheres and methods of using them |
| ATE221379T1 (de) | 1991-05-01 | 2002-08-15 | Jackson H M Found Military Med | Verfahren zur behandlung infektiöser respiratorischer erkrankungen |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| DE69231123T2 (de) | 1992-03-25 | 2001-02-15 | Immunogen Inc | Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065 |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
| DE69630514D1 (de) | 1995-01-05 | 2003-12-04 | Univ Michigan | Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| WO1997007788A2 (en) | 1995-08-31 | 1997-03-06 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
| DK0885002T3 (da) | 1996-03-04 | 2011-08-22 | Penn State Res Found | Materialer og fremgangsmåder til forøgelse af cellulær internalisering |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| ATE287257T1 (de) | 1997-01-16 | 2005-02-15 | Massachusetts Inst Technology | Zubereitung von partikelhaltigen arzneimitteln zur inhalation |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| GB2339430A (en) | 1997-05-21 | 2000-01-26 | Biovation Ltd | Method for the production of non-immunogenic proteins |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| AU747231B2 (en) | 1998-06-24 | 2002-05-09 | Alkermes, Inc. | Large porous particles emitted from an inhaler |
| JP2002532415A (ja) | 1998-12-16 | 2002-10-02 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤による関節炎の治療 |
| ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
| WO2000061739A1 (fr) | 1999-04-09 | 2000-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle |
| JP2003514903A (ja) | 1999-11-24 | 2003-04-22 | イムノージェン インコーポレーテッド | タキサンを含有する細胞傷害薬とその治療への利用 |
| DK1242438T3 (da) | 1999-12-29 | 2007-02-12 | Immunogen Inc | Cytotoksiske midler omfattende modificerede doxorubiciner og daunorubiciner og deres terapeutiske anvendelse |
| US6960614B2 (en) | 2000-07-19 | 2005-11-01 | Warner-Lambert Company | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids |
| US6411163B1 (en) | 2000-08-14 | 2002-06-25 | Intersil Americas Inc. | Transconductance amplifier circuit |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| NZ532526A (en) | 2001-10-25 | 2007-01-26 | Genentech Inc | Compositions comprising a glycoprotein having a Fc region |
| CN101717410B (zh) | 2002-02-01 | 2015-04-29 | 阿里亚德医药股份有限公司 | 含磷化合物及其应用 |
| NZ535101A (en) | 2002-03-08 | 2007-07-27 | Eisai Co Ltd | Macrocyclic compounds useful as pharmaceuticals |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| GB0215823D0 (en) | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
| EP1578777B1 (en) | 2002-07-15 | 2008-11-26 | The Trustees of Princeton University | Iap binding compounds |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| ZA200601182B (en) * | 2003-10-10 | 2007-04-25 | Immunogen Inc | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| CA2550245A1 (en) | 2003-12-19 | 2005-07-21 | Five Prime Therapeutics, Inc. | Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention |
| CN1933847A (zh) | 2004-01-16 | 2007-03-21 | 密歇根大学董事会 | Smac肽模拟物及其应用 |
| CA2553874A1 (en) | 2004-01-16 | 2005-08-04 | The Regents Of The University Of Michigan | Conformationally constrained smac mimetics and the uses thereof |
| AU2005228950B2 (en) | 2004-03-23 | 2012-02-02 | Genentech, Inc. | Azabicyclo-octane inhibitors of IAP |
| ES2394441T3 (es) | 2004-04-07 | 2013-01-31 | Novartis Ag | Inhibidores de IAP |
| DK1778718T3 (da) | 2004-07-02 | 2014-11-10 | Genentech Inc | Iap-inhibitorer |
| US7674787B2 (en) | 2004-07-09 | 2010-03-09 | The Regents Of The University Of Michigan | Conformationally constrained Smac mimetics and the uses thereof |
| EP2457895A1 (en) | 2004-07-12 | 2012-05-30 | Idun Pharmaceuticals, Inc. | Tetrapeptide analogs |
| JP5230865B2 (ja) | 2004-07-15 | 2013-07-10 | テトラロジック ファーマシューティカルズ コーポレーション | Ｉａｐ結合性化合物 |
| ES2349110T5 (es) | 2004-12-20 | 2013-11-27 | Genentech, Inc. | Inhibidores de IAP derivados de pirrolidina |
| US20110166319A1 (en) | 2005-02-11 | 2011-07-07 | Immunogen, Inc. | Process for preparing purified drug conjugates |
| WO2006086733A2 (en) | 2005-02-11 | 2006-08-17 | Immunogen, Inc. | Process for preparing maytansinoid antibody conjugates |
| EP1868649A4 (en) | 2005-04-15 | 2011-06-29 | Immunogen Inc | ELIMINATION OF A POPULATION OF HETEROGENEOUS OR MIXED CELLS IN TUMORS |
| US20080044420A1 (en) | 2005-05-11 | 2008-02-21 | Heavner George A | Anti-IL-13 antibodies, compositions, methods and uses |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| ES2434470T3 (es) | 2005-07-08 | 2013-12-16 | Biogen Idec Ma Inc. | Anticuerpos SP35 y usos de éstos |
| CA2618218C (en) | 2005-07-21 | 2015-06-30 | Ardea Biosciences, Inc. | N-(arylamino)-sulfonamide inhibitors of mek |
| NZ595430A (en) | 2005-08-24 | 2013-05-31 | Immunogen Inc | Process for preparing maytansinoid antibody conjugates |
| KR20080080482A (ko) | 2005-09-07 | 2008-09-04 | 메디뮨 엘엘씨 | 독소가 컨쥬게이트된 ｅｐｈ 수용체 항체 |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| US8945572B2 (en) | 2006-05-12 | 2015-02-03 | Genentech, Inc. | Methods and compositions for the diagnosis and treatment of cancer |
| AU2008245447C1 (en) | 2007-04-30 | 2014-11-20 | Genentech, Inc. | Inhibitors of IAP |
| JP5658565B2 (ja) | 2007-09-12 | 2015-01-28 | ジェネンテック， インコーポレイテッド | ホスホイノシチド３−キナーゼ阻害剤化合物と化学療法剤との組合せ、および使用方法 |
| JP5348725B2 (ja) | 2007-10-25 | 2013-11-20 | ジェネンテック， インコーポレイテッド | チエノピリミジン化合物の製造方法 |
| WO2012021841A2 (en) | 2010-08-12 | 2012-02-16 | Attogen Inc. | Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof |
| WO2009100105A2 (en) | 2008-02-04 | 2009-08-13 | Attogen Inc. | Inhibitors of oncogenic isoforms and uses thereof |
| CN104524592B (zh) * | 2008-04-30 | 2018-06-05 | 伊缪诺金公司 | 交联剂和它们的用途 |
| CA2725873C (en) * | 2008-05-29 | 2018-05-01 | Galaxy Biotech, Llc | Monoclonal antibodies to basic fibroblast growth factor |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| WO2010120561A1 (en) | 2009-04-01 | 2010-10-21 | Genentech, Inc. | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
| KR101947176B1 (ko) | 2009-06-03 | 2019-02-12 | 이뮤노젠 아이엔씨 | 접합 방법 |
| JP2013506709A (ja) * | 2009-10-06 | 2013-02-28 | イミュノジェン・インコーポレーテッド | 有効なコンジュゲートおよび親水性リンカー |
| TWI507524B (zh) * | 2009-11-30 | 2015-11-11 | Genentech Inc | 診斷及治療腫瘤之組合物及方法 |
| US9145462B2 (en) | 2010-06-30 | 2015-09-29 | The Regents Of The University Of California | Glioblastoma multiforme-reactive antibodies and methods of use thereof |
| EP2640727B1 (en) | 2010-11-17 | 2015-05-13 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
| CA2831562A1 (en) | 2011-03-29 | 2012-10-04 | Immunogen, Inc. | Process for manufacturing conjugates of improved homogeneity |
| EA201991268A3 (ru) | 2011-03-29 | 2020-01-31 | Иммуноджен, Инк. | Получение конъюгатов "майтансиноид-антитело" одностадийным способом |
| WO2014089193A1 (en) | 2012-12-04 | 2014-06-12 | Aveo Pharmaceuticals, Inc. | Anti-fgfr2 antibodies |
| US9415118B2 (en) | 2013-03-13 | 2016-08-16 | Novartis Ag | Antibody drug conjugates |
| US11605302B2 (en) | 2020-11-10 | 2023-03-14 | Rockwell Collins, Inc. | Time-critical obstacle avoidance path planning in uncertain environments |
-
2014
- 2014-03-11 US US14/203,997 patent/US9498532B2/en not_active Expired - Fee Related
- 2014-03-12 TW TW103108773A patent/TW201444574A/zh unknown
- 2014-03-12 UY UY0001035399A patent/UY35399A/es not_active Application Discontinuation
- 2014-03-13 KR KR1020157026812A patent/KR20150130333A/ko not_active Ceased
- 2014-03-13 MX MX2015012122A patent/MX2015012122A/es unknown
- 2014-03-13 CN CN201480021393.2A patent/CN105188763B/zh not_active Expired - Fee Related
- 2014-03-13 BR BR112015023418A patent/BR112015023418A8/pt not_active Application Discontinuation
- 2014-03-13 EA EA201591611A patent/EA201591611A1/ru unknown
- 2014-03-13 EP EP14729099.3A patent/EP2968592A2/en not_active Withdrawn
- 2014-03-13 AU AU2014244060A patent/AU2014244060B2/en not_active Ceased
- 2014-03-13 CA CA2904090A patent/CA2904090A1/en not_active Abandoned
- 2014-03-13 AR ARP140100924A patent/AR096015A1/es unknown
- 2014-03-13 JP JP2016502005A patent/JP2016518332A/ja active Pending
- 2014-03-13 WO PCT/US2014/025944 patent/WO2014160160A2/en not_active Ceased
-
2016
- 2016-10-11 US US15/291,024 patent/US20170106095A1/en not_active Abandoned
-
2017
- 2017-03-31 AU AU2017202150A patent/AU2017202150B2/en not_active Ceased
-
2019
- 2019-04-18 JP JP2019079590A patent/JP2019193626A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016518332A5 (enExample) | ||
| JP2018501781A5 (enExample) | ||
| JP2016512832A5 (enExample) | ||
| CN111587124B (zh) | Ror1抗体免疫缀合物 | |
| JP7137474B2 (ja) | ＮａＰｉ２ｂ標的化抗体－薬物コンジュゲート及びその使用方法 | |
| Stephan et al. | Challenges in developing bioanalytical assays for characterization of antibody–drug conjugates | |
| JP6333882B2 (ja) | 抗体−薬剤コンジュゲート | |
| JP2021516960A5 (enExample) | ||
| US20210380680A1 (en) | Anti-claudin antibodies and uses thereof | |
| CN110869393A (zh) | 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途 | |
| JP6282745B2 (ja) | 修飾抗上皮成長因子受容体抗体およびその使用法 | |
| US20240033369A1 (en) | Anti-cd228 antibodies and antibody-drug conjugates | |
| RU2020103344A (ru) | Конъюгаты антител с лекарственными средствами, характеризующиеся высокой in vivo переносимостью | |
| US12252746B2 (en) | Anti-CD46 antibodies and methods of use | |
| EP4378958A3 (en) | High-affinity anti-mertk antibodies and uses thereof | |
| RU2017102988A (ru) | Антитела против рецептора фолиевой кислоты 1, их иммуноконъюгаты и использование | |
| CN113784987B (zh) | 靶向磷脂酰肌醇蛋白聚糖-1的高亲和力单克隆抗体和使用方法 | |
| JP2018520092A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| JP2020526584A5 (enExample) | ||
| CN116808198A (zh) | 包含抗-ly75抗体的医药组合 | |
| JP2025061007A5 (enExample) | ||
| CN119317447A (zh) | 抗可变muc1*抗体及其用途 | |
| CN120787163A (zh) | 抗体药物缀合物 | |
| WO2025213130A1 (en) | Antibody drug conjugates |